Johnson & Johnson announces collaboration with HP Inc. subsidiary to create personalized health care solutions with 3D printing technologies

Johnson & JohnsonJohnson & Johnson (NYSE: JNJ) today announced a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. The collaboration is focused on using 3D printing technologies to create better health care outcomes at reduced costs. Working together, the companies plan to combine their scientific, clinical, material science and technological expertise, and deep insights to develop products and solutions which can be manufactured quickly and customized to the needs of an individual patient or consumer.

In the near-term, the collaboration will focus on personalization of instrumentation and software for patient-specific healthcare devices. It is anticipated that 3D printing technology will lead to innovation in areas such as orthopaedics, eye health and consumer products, among others.

"The intersection of technology and health care is spurring innovation that will have a profound impact on patients and consumers all over the world," said Sandra Peterson, Group Worldwide Chairman, Johnson & Johnson. "Combined with advances in data mining and software, 3D printing could enable distributed manufacturing models and patient-specific products, therapies and solutions that deliver better outcomes, better economics and improved global accessibility. This collaboration with HP Inc. exemplifies our commitment to harnessing new technology to improve outcomes and reduce costs across the health continuum."

"Advances in 3D printing technology have the potential to break historical paradigms of health care delivery in ways that are not feasible in traditional manufacturing processes," said Stephen Nigro, president of HP's 3D printing business. "Together with Johnson & Johnson we have the potential to create opportunities and innovations in health care to improve patients’ lives that neither company could develop alone."

The collaboration announced today has already begun, with teams of experts from both organizations working together.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Most Popular Now

ACE2 protein protects against severe COVID-19

Female COVID-19 patients face less severe disease complications and a lower risk of dying than male patients thanks to hormones and chromosomes that contribute to a stron...

Neutralizing antibodies protect against severe COV…

Understanding the body's immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines. Of particular...

How SARS-CoV-2 interacts with cells

SARS-CoV-2 infections pose a global threat to human health and a formidable research challenge. One of the most urgent tasks is to gain a detailed understanding of the mo...

Valneva initiates Phase 1/2 clinical study of inac…

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced the initiation of a Phase 1/2 clinical study for it...

Vir Biotechnology and GSK announce start of NIH-sp…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in a new sub-trial of the National Ins...

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EM...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

Pfizer and BioNTech receive authorization in the E…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...